自身免疫性疾病患者血清抗bFGF自身抗体的检测及对疾病诊断价值的临床分析

为探讨自身免疫性疾病(autoimmune disease,AID)患者血清中抗碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)自身抗体水平及对患者的诊断价值,回顾性收集2015年3月至2017年5月医院收治的AID患者80例为观察组,取同期入院健康体检者80例为对照组。采用ELISA检测2组患者血清中抗bFGF抗体IgM和IgG水平。结果显示80例AID患者经过检测血清中抗bFGF自身抗体均得到确诊,排在前3位的分别为SLE、RA及慢性肾炎,分别占28.75%、22.50%和18.75%;观察组bFGF水平高于对照组(t=7.572,P0.05);观察组中SLE、不明原因发热患者抗bFGF IgM抗体与对照组比较差异无统计学意义;观察组RA、皮肌炎及特发性血小板减少性紫癜患者抗bFGF IgG抗体阳性率高于对照组(P0.05);观察组RA、慢性肾炎、皮肌炎、特发性血小板减少性紫癜患者抗bFGF IgM抗体水平高于对照组(P0.05)。由此AID患者血清中存在bFGF自身抗体水平升高现象,加强抗bFGF自身抗体水平测定有助于AID的诊断,值得推广应用。     

13种自身抗体检测对SLE的诊断价值及临床意义

目的探讨13种自身抗体对系统性红斑狼疮（SLE）的诊断价值和临床意义。方法抗核抗体（ANA）的检测采用间接免疫荧光法;抗ds-DNA抗体的检测采用快速金标渗滤法;11种可抽提核抗原（ENA）抗体的检测采用免疫印迹法。结果（1）223例SLE患者抗核抗体谱中,ANA、ds-DNA及抗ENA抗体SS-A/Ro60、SmD1、SS-A/Ro52和U1-RNP的阳性率较高,分别为95.06%、52.91%、50.22%、27.35%、24.66%和21.08%;Jo-1和P0抗ENA抗体的阳性率较低,分别为1.79%和0.90%;正常对照组仅ANA有5%的阳性率,其余抗体均为阴性。（2）抗体阳性的患者主要集中在10～50岁之间,10岁以下和50岁以上的患者比较少,平均年龄35岁。（3）SLE患者ANA-LIA的检测大多数患者的条带在4条以内,随着条带的增多,患者的数量减少。（4）抗ds-DNA抗体与抗SmD1抗体、抗核小体抗体的阳性率有显著差异（P〈0.01）,与抗SS-A/Ro60抗体的阳性率比较无显著差异（P〉0.05）。抗SmD1抗体与抗核小体、抗SS-A/Ro60抗体的阳性率有显著差异（分别为P〈0.05和P〈0.01）,与抗U1-RNP抗体的阳性率无显著差异（P〉0.05）。（5）104例SLE患者的血清免疫球蛋白和补体水平的异常,主要体现在IgG和C3异常。结论自身抗体的检测对SLE的诊断、治疗和疗效观察具有重要意义,多项自身抗体联合检测有利于提高SLE的免疫学诊断的阳性率。     

自身抗体检测在自身免疫性疾病中的价值

目的:探讨ENA(抗可提取性核抗原抗体)、ANA(抗核抗体)和抗ds-DNA抗体(双链DNA抗体)在AID患者中的相关性及敏感性。方法:分析2013年2月至2014年4月在我院接受治疗的AID患者的临床资料。检测入组患者的ENA、ANA、抗ds-DNA抗体表达情况。比较男性、女性的自身抗体阳性情况差异,并探讨不同荧光模式的ANA对应的ENA各项阳性情况以及ANA表达与ENA、抗ds-DNA表达相关性。结果:本研究共纳入研究对象180例,其中男性患者67例,女性患者113例。女性患者的ANA(χ2=12.23,P0.01)、抗ds-DNA阳性率(χ2=5.906,P=0.015)均显著高于男性。nRNP、ss-A阳性标本中的颗粒型ANA比例最高,而Scl-70阳性标本中均质型ANA比例最高;ANA阳性标本的ENA阳性率(χ2=6.406,P=0.011)、抗ds-DNA阳性率(χ2=43.49,P0.01)显著高于ANA阴性的标本。结论:男性自身抗体阳性率明显低于女性,颗粒型在ANA核型中占据比较高的比率,抗ds-DNA和ENA的阳性检出率与ANA阳性率有着一定的关系。     

流式荧光免疫技术检测抗核抗体谱的性能与临床应用评价

目的 分析流式荧光免疫技术(FFIA)检测自身抗体谱的结果及评价其在系统性红斑狼疮(SLE)诊断中的应用价值。方法 用流式荧光免疫法和免疫印迹法同时检测219例自身免疫病患者(包括92例SLE患者和127例非SLE的其他自身免疫病患者)、231例其他疾病患者、50例健康体检者血清的特异性自身抗体(抗nRNP、Sm、SS-A、SS-B、Jo-1、Scl-70、rRNP、PCNA、Nucleosome、Histone、CenP-B、M2、dsDNA),计算两种方法的阴阳符合率,并采用Kappa检验评估结果一致性;采用受试者工作特征曲线(ROC)比较各抗体在系统性红斑狼疮诊断中的应用价值。结果 FFIA与免疫印迹法检测各项自身抗体总符合率在87%至98%之间,Kappa值在0.179至0.854之间,其中抗CenP-B抗体一致性最好(Kappa值=0.854),抗His抗体一致性最差(Kappa值=0.179)。在219例自身免疫病例组数据中,根据试剂盒给定的阳性结果判断标准得到的免疫印记法灵敏度(62.0%)高于流式荧光(44.6%),而特异性略低于后者,分别为89.8%和94.4%,但二...     

抗核抗体谱检测在诊断系统性红斑狼疮中的意义

探讨抗核抗体(ANA)和抗核抗体谱(ANAs)检测对诊断系统性红斑狼疮(SLE)患者的临床意义。用间接免疫荧光法(IIF)和免疫印迹法检测106例SLE组和30名对照组血清ANA及ANAs中的12种抗体。结果表明:SLE组ANA阳性率为86.8%,ANAs中抗ds-DNA、抗Scl-70、抗Jo-1、抗nRNP、抗Sm、抗SS-A、抗SS-B、抗Ro-52、抗CENP-B、抗AnuA、抗AHA和抗核糖体P蛋白的阳性率分别为28.3%、0.9%、0.9%、35.9%、17.0%、39.6%、18.9%、41.5%、9.4%、29.3%、31.1%和9.4%。ANA和ANAs联合检测提高了诊断的敏感性,对SLE的诊断和治疗有重要意义。     

87例抗核抗体斑点型阳性患者血清特异性抗核抗体谱分析

目的探讨血清斑点型抗核抗体（ANA）与特异性抗核抗体谱（ANAS）中不同项目阳性组合之间的相关性。方法分析87例斑点型ANA阳性病例的抗ANAS（抗Ul-nRNP、Sm、SS-A、SS—B、Scl-70、Jo-1、SCL-70、PM—Scl、centromereB、nukleosome、PCNA、ds—DNA、histones、ribosomal—Pprotein、AMA-M2抗体）多肽谱类型。结果斑点型ANA的特异性ANAS不同项目阳性组合类型达到23种,除SCL-70、PM—Scl外,其他13种特异性ANAS成分均见阳性。ds—DNA阴性的histone、Sm、nukleosome、PCNA、Rib-P．P单独阳性或合并其他抗体阳性率高达19．5％（17／87）,联合检测这些抗体能提高系统性红斑狼疮（SLE）诊断的敏感性。ANAS阳性率与ANA滴度之间没有绝对关系。结论不能简单地依据荧光核型来推断抗ANAS抗体的具体类型;多项指标联合检测能提高诊断疾病的敏感性和特异性;斑点型ANA低滴度时也应作特异性ANAS检测。     

中国西部自身免疫性肝病患者自身抗体的分布特征

目的: 探讨中国西部自身免疫性肝病患者中相关自身抗体的存在状况及特征.方法: 57例自身免疫性肝病患者分为3组: 自身免疫性肝炎(AIH)12例、原发性胆汁性肝硬化(PBC)32例、原发性硬化性胆管炎(PSC)13例.用间接免疫荧光法检测抗核抗体(ANA)、平滑肌抗体(SMA)、抗肝肾微粒抗体1型抗体(anti-LKM1)、抗线粒体抗体(AMA)和抗中性粒细胞胞质抗体(ANCA),Western blot检测抗肝细胞胞溶质抗原1型抗体(anti-LC1)、抗可溶性肝抗原/肝胰抗原抗体(anti-SLA/LP)、抗肝肾微粒抗体1型(anti-LKM1)、 AMA-M2亚型等多种肝抗原自身抗体.结果: 57例中ANA、AMA、M-2、pANCA阳性率在组间有统计学差异(P<0.01).PBC中AMA、M-2阳性检出率均为100%, PSC中pANCA阳性检出率为53.8%, Fisher精确检验在α'=0.002水准与其他各组比较有统计学差异.AIH与PBC的ANA阳性率分别为100%和50%,Fisher精确检验在α'=0.002水准二者无统计学意义,与其他各组比较有明显差异.在AIH组SMA阳性率为25%,LKM-1、LC-1、SLA/LP阳性率均为8.3%, 与其他组无统计学意义,可能与病例少有关.PBC中分别有1例患者ANA、SMA以及ANA、LKM-1同时阳性, PSC中有1例ANA、SLA/LP同时阳性,此3例患者结合性别、生化、自身抗体等资料符合AIH诊断条件;AIH中有1例M-2阳性综合各项资料符合PBC(重叠综合征).结论: 肝抗原自身抗体、ANA、AMA及M-2亚型的检测有助于自身免疫性肝病的诊断.对肝炎病毒血清标志物阴性的肝功能异常者应该行肝抗原自身抗体检测协助诊断.     

自身抗体联合检测对系统性红斑狼疮诊断的意义

为了评价抗核小体抗体(anti-nucleosome antibody,AnuA)、抗Sm抗体、抗双链DNA(double stranded-DNA,dsDNA)抗体、抗核糖体P蛋白(ribosomal P protein,rRNP)抗体联合检测对系统性红斑狼疮(SLE)诊断的价值,采用酶联免疫吸附法(ELISA)测定123例SLE患者、61例其他结缔组织病患者和30名健康对照者血清中An.uA、抗dsDNA抗体、抗Sm抗体、抗rRNP抗体含量.结果显示,AnuA、抗dsDNA抗体、抗Sm抗体和抗rRNP抗体在SLE患者中的阳性率明显高于疾病对照组和正常对照组;AnuA与抗dsDNA抗体的敏感性显著高于其他两种自身抗体;抗dsDNA抗体、抗sm抗体和抗rRNP抗体阴性的SLE患者中,AnuA阳性率为52.6%～68.0%;SLE活动期患者与非活动期患者AnuA、抗dsDNA抗体阳性率有显著性差别.四种自身抗体在SLE的诊断中有明显的互补作用,特别是AnuA和抗dsDNA抗体可以弥补其他抗体的不足;AnuA、抗dsDNA抗体与疾病活动性密切相关.AnuA与抗sm抗体或AnuA与抗dsDNA抗体的二联检测可明显提高其对SLE诊断的敏感性.AnuA、抗dsDNA抗体、抗Sm抗体三联检测的阳性率可达87%.自身抗体联合检测提高了诊断的敏感性,对SLE的诊断和治疗有重要意义.     

自身抗体联合体液免疫检测在SLE中的应用价值

目的 探讨联合检测自身抗体、免疫球蛋白和补体在系统性红斑狼疮(SLE)诊断和病情判断中的应用价值.方法 选取SLE患者54例、其他自身免疫性疾病患者32例和正常对照30例,采用间接免疫荧光法测定抗核抗体(ANA)、免疫印迹法测定抗核提取物抗体(抗ENA抗体)、散射免疫比浊法测定免疫球蛋白和补体C3、C4.结果 SLE患者的ANA、抗dsDNA、抗Sm、抗核小体、抗U1-nRNP、抗核糖体P蛋白、抗组蛋白抗体的检测阳性率分别为87.04％、59.26％、27.78％、29.63％,37.04％、12.96％、27.78％;SLE活动组中抗dsDNA和抗核小体抗体的阳性率高于SLE非活动组,差异具有统计学意义(P＜0.05);SLE活动组IgG、IgA、IgM水平高于正常对照组,C3、C4水平低于正常对照组,差异具有统计学意义(P＜0.01).结论 自身抗体联合免疫球蛋白和补体检测对SLE患者的临床诊断和病情判断有良好的参考价值.     

四种自身抗体联检对SLE诊断的临床价值

目的：探讨抗核抗体（ANA）、抗双链DNA（ds-DNA）抗体、抗Sm抗体和抗核糖体P蛋白（r-RNP）抗体联检对系统性红斑狼疮（SLE）诊断的临床价值。方法：检测49例SLE患者、33例其他结缔组织病患者（对照组）和40名正常人血清ANA、抗ds-DNA抗体、抗Sm抗体和抗r-RNP抗体。结果：ANA、抗ds-DNA抗体、抗Sm抗体和抗r-RNP抗体在SLE患者中的阳性率明显高于对照组和正常人组（P〈0.01）;ANA与抗ds-DNA抗体的敏感性显著高于其他两种自身抗体（P〈0.05）;SLE活动期患者与非活动期患者抗ds-DNA抗体阳性率有显著性差别（P〈0.01）;抗ds-DNA抗体滴度与SLE-DAI呈正相关（r=0.57,P〈0.01）;ANA、抗ds-DNA抗体、抗Sm抗体和抗r-RNP抗体联检的敏感性可达98.0%。结论：自身抗体联检提高了SLE诊断的敏感性,对SLE的诊断和治疗有重要意义。     

The significance of some immunoserologic diagnostic tests in systemic diseases

The sensitivity and specificity of immunoserologic tests included in the diagnostic criteria of systemic lupus erythematosus are shown. The frequencies of some rare autoantibodies (PCNA, PL-4, SL, PM-Scl, Scl-70, Jo-1) in systemic connective tissue diseases of mixed Yugoslav population are demonstrated. The results from different laboratories differ considerably and the possible reasons are described.     

The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies

The presence of autoantibodies to the Ro52 protein in sera from patients with idiopathic inflammatory myopathies has recently been reported. These antibodies were found predominately in sera with the myositis-specific autoantibody anti-histidyl-tRNA synthetase (anti-Jo-1). In this report, we analysed sera from 216 patients to determine whether anti-Ro52 antibodies are associated with myositis autoantibodies other than anti-Jo-1. These included sera containing antibodies that recognize threonyl- or alanyl-tRNA synthetases, Mi-2, PM-Scl, signal recognition particle (SRP), as well as the systemic sclerosis-related antibodies anti-topoisomerase I (Scl-70) and anti-centromere. A high proportion of sera that contain anti-aminoacyl-tRNA synthetase antibodies, anti-SRP, or anti-PM-Scl antibodies were found to contain antibodies to the Ro52 protein. In contrast, in sera containing anti-Mi-2, anti-Scl-70 or anti-centromere antibodies, anti-Ro52 antibodies were absent or occurred infrequently. In addition, only one serum from 41 rheumatoid arthritis patients was positive for anti-Ro52 autoantibodies. These data indicate that anti-Ro52 antibodies are produced in particular subsets of myositis patients, and are not limited to sera with anti-Jo-1 antibodies.     

Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases

BACKGROUND: Multiplexed assays using fluorescence microspheres is an exciting technology with multiple applications including the detection of antinuclear autoantibodies (ANA) and autoantibody profiles. It is a rapid, sensitive and automatic method for simultaneous quantitative detection of several autoantibodies. The aim of our study was to determinate ANA and other autoantibodies to the nine extractable nuclear antigens by the AtheNA Multi-Lyte ANA system and compare the results achieved by this method to the routinely used enzyme immunoassay. METHODS: Four hundred eighteen serum samples were tested utililizing the multiplexed method: 96 healthy donors, 86 requested ANA specimens obtained from routine lab, and 236 samples from patients with known autoimmune diseases (43-scleroderma, 113-systemic lupus erythematosus, 38-Sjogren's syndrome, and 42 rheumatoid arthritis). The ANA and antibodies to nine different analytes (SS/A, SS/B, Sm, RNP, Jo-1, Scl-70, dsDNA, Centromere B and Histone) were tested. RESULTS: ANA screening by AtheNA system revealed high concordance of 99 and 97.7% with the enzyme immunoassay test in samples obtained from healthy donors and ANA requested samples, respectively. Evaluation of autoimmune disease-related samples for ANA by AtheNA technology also confirmed a high rate of concordance of 92-97.7% and correlated with the enzyme immunoassay. Positive discrepant results were found for Scl-70 specificity in 12.7% of SLE specimens by AtheNA technology, while all tested sera were negative for this antibody by enzyme immunoassay. Negative discrepant results were observed by the AtheNA system for anti-dsDNA. The sera (15 randomly obtained samples from SLE patients) were positive for anti-dsDNA in 50% of samples in Farr assay and 55% in enzyme immunoassay, respectively. CONCLUSION: We suggest that the AtheNA technology may be a useful diagnostic tool for ANA screening. Additional investigations are required to compare an analytic performance between AtheNA and routine methods in determination of the individual autoantibody profile.     

Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases

Background: Multiplexed assays using fluorescence microspheres is an exciting technology with multiple applications including the detection of antinuclear autoantibodies (ANA) and autoantibody profiles. It is a rapid, sensitive and automatic method for simultaneous quantitative detection of several autoantibodies. The aim of our study was to determinate ANA and other autoantibodies to the nine extractable nuclear antigens by the AtheNA Multi-Lyte ANA system and compare the results achieved by this method to the routinely used enzyme immunoassay.

Methods: Four hundred eighteen serum samples were tested utililizing the multiplexed method: 96 healthy donors, 86 requested ANA specimens obtained from routine lab, and 236 samples from patients with known autoimmune diseases (43-scleroderma, 113-systemic lupus erythematosus, 38-Sjogren's syndrome, and 42 rheumatoid arthritis). The ANA and antibodies to nine different analytes (SS/A, SS/B, Sm, RNP, Jo-1, Scl-70, dsDNA, Centromere B and Histone) were tested.

Results: ANA screening by AtheNA system revealed high concordance of 99 and 97.7% with the enzyme immunoassay test in samples obtained from healthy donors and ANA requested samples, respectively. Evaluation of autoimmune disease-related samples for ANA by AtheNA technology also confirmed a high rate of concordance of 92–97.7% and correlated with the enzyme immunoassay. Positive discrepant results were found for Scl-70 specificity in 12.7% of SLE specimens by AtheNA technology, while all tested sera were negative for this antibody by enzyme immunoassay. Negative discrepant results were observed by the AtheNA system for anti-dsDNA. The sera (15 randomly obtained samples from SLE patients) were positive for anti-dsDNA in 50% of samples in Farr assay and 55% in enzyme immunoassay, respectively.

Conclusion: We suggest that the AtheNA technology may be a useful diagnostic tool for ANA screening. Additional investigations are required to compare an analytic performance between AtheNA and routine methods in determination of the individual autoantibody profile.     

应用免疫印迹技术检测抗Scl-70和抗Jo-1抗体

本文通过对兔胸腺可抽提核抗原(ENA)制备方法的改良应用免疫印迹技术(IBT)检测抗Scl-70与抗 Jo-1抗体,对 157例各种风湿性疾病及 36名正常人的对照研究,表明 70 kD(Scl-70)多肽抗体是进行性系统性硬化症(PSS)伴弥漫性硬皮病(DS)的标记抗体,阳性率为45.5％,而55kD(Jo-1)多肽抗体是多发性肌炎(PM)的标记抗体,阳性率为25％。     

系统性红斑狼疮患者抗β2-糖蛋白Ⅰ抗体检测及其临床意义

目的 探求抗β2-糖蛋白Ⅰ(β2glyeoprotein Ⅰ,β2-GP Ⅰ抗体IgG、IgA、IgM在系统性红斑狼疮(SLE)临床的测定.方法 采用酶联免疫吸附试验(ELISA)检测100例SLE患者、39例疾病对照组(包括类风湿关节炎、硬化症、干燥综合征、自身免疫性肝病和混合性结缔组织病)和30例正常人群血清抗β2-GP 1抗体、抗心磷脂抗体(ACL)IgC、IgA、IgM等指标,分析其与临床特点(如血栓、流产)的关系.结果 SLE组抗β2-GP Ⅰ抗体(IgG、IgA、IgM)浓度高于正常对照组,差异具有统计学意义(P<0.01),敏感性、特异性、阳性预测值、阴性预测值分别为17.2%、95.7%、85.0%、44.6%.β2-GPⅠ抗体(IgG、IgA、IgM)与ACL抗体(IgG、IgA、IgM)两者呈正相关(r值分别为0.418、0.624、0.518、0.583,P<0.01).以SLE DAI为因变量对β2-GPⅠ抗体、ACL抗体、dsDNA、u1-RNP、Sm、SSA、SSB、Sc1-70、Jo-1、P.蛋白、PT、APTT进行Logistic回归统计分析,入选的自变量有β2-GPⅠ·IgC和dsDNA.结论 抗β2GP Ⅰ抗体在SLE中具有一定敏感性和较高的特异性,与SLE的血栓形成相关,且抗β2-CPⅠ抗体IgG是SLE疾病活动性危险因素之一.检测抗β2-GPⅠ抗体在SLE中存在一定临床应用价值.     

Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis

Fully automated multiplex immunoassays are increasingly used as first line screening for antinuclear antibodies. The diagnostic performance of such multiplex assays in untreated patients at the time of diagnosis has not been reported.Antinuclear antibodies were measured by indirect immunofluorescence (IIF) (dilution 1:160) and by BioPlex 2200 ANA screen (antibodies to dsDNA, chromatin, ribosomal protein, SSA-52, SSA-60, SSB, Sm, SmRNP, RNP-A, RNP-68, Scl-70, Jo-1, and centromere B) in 236 patients with a systemic rheumatic disease at the time of diagnosis, 149 blood donors, 139 patients with chronic fatigue syndrome (CFS), and 134 diseased controls.BioPlex ANA screen and IIF were positive in, respectively, 79% and 90% of patients with systemic lupus erythematosus (SLE), 60% and 60% with cutaneous lupus, 72% and 93% with systemic sclerosis (SSc), 100% and 100% with mixed connective tissue disease (MCTD), 89% and 56% with primary Sjögren's (SS) syndrome, 36% and 36% with polymyositis/dermatomyositis, 5.4% and 6% of blood donors, 7.2% and 3.6% of patients with CFS, and 11% and 18% of diseased controls. BioPlex test result interval specific likelihood ratios increased with increasing antibody concentration. The simultaneous presence of at least three antibodies by BioPlex was found in 35% of patients with SLE, 4% with SSc, 100% with MCTD, 64% with SS, 7% with inflammatory myopathy, 0.7% of CFS and diseased controls, and none of the blood donors.In conclusion, test result specific likelihood ratios and the presence of multiple autoantibodies help with the interpretation of data generated by multiplex immunoassays.     

Antiribonuclease H2 antibodies are an immune biomarker for systemic lupus erythematosus

We previously reported that autoantibodies against the proliferating cell nuclear antigen protein (PCNA)-binding protein chromatin assembly factor-1 (CAF-1) are specifically found in patients with systemic lupus erythematosus (SLE). PCNA and its complex constituents elicit autoimmune responses in patients with SLE, suggesting that autoantibody diversification likely occurs owing to epitope spreading. Therefore, we sought to clarify whether patients with SLE exhibit an autoimmune response to Ribonuclease H2 (RNase H2), another PCNA-binding protein that regulates cell division. As results, RNase H2 autoantibodies were detected in the sera of 33.9% (19/56) of SLE patients, which was significantly higher than that observed in sera from other patients with systemic autoimmune diseases (polymyositis/dermatomyositis, systemic sclerosis, Sjogren’s syndrome, mixed connective tissue disease and rheumatoid arthritis) and healthy controls. Regression analysis also showed that serum anti-RNase H2 levels were strongly correlated to that of CAF-1 in SLE patients. Our data support the use of RNase H2 autoantibodies as a serum biomarker for SLE diagnosis. Moreover, the strong correlation observed between RNase H2 and CAF-1 suggests that intermolecular epitope spreading may play a critical role in autoantibody production and diversification in SLE.     

自身抗体联合检测对系统性红斑狼疮的诊断价值

研究抗核抗体(ANA)、抗双链DNA(ds-DNA)抗体、抗Smith(Sm)抗体、抗核小体抗体(AnuA)和抗核糖体P蛋白抗体(ARPA)5种自身抗体单项及联合检测系统性红斑狼疮(SLE)诊断中的价值.测定了66例SLE患者和50例其他疾病患者(对照组)血清中的自身抗体.以间接免疫荧光法测定ANA;免疫印迹法测定抗ds-DNA抗体、抗Sm抗体、AnuA和ARPA.结果显示,在66例SLE患者中ANA、抗ds-DNA抗体、抗Sm抗体、AnuA和ARPA的阳性率分别为92.4%、27.2%、42.4%、71.2%和16.6%,均明显高于对照组(32%、2%、2%、4%和2%)(P＜0.01);ANA、AnuA的敏感性明显高于其他3种抗体(P＜0.01);ANA、抗ds-DNA抗体、抗Sm抗体、AnuA和ARPA的特异性分别为68.0%、98.0%、98.0%、96.0%和98.0%.结论:抗ds-DNA抗体、抗Sm抗体、AnuA和ARPA等4种自身抗体对SLE的检测有很高的特异性,且有明显的互补作用,联合检测能提高对SLE检测的敏感性.